Yale Cancer Center NCTN
耶鲁大学癌症中心 NCTN
基本信息
- 批准号:8839216
- 负责人:
- 金额:$ 55.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-04-16 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:Advanced Malignant NeoplasmAdvocateAllyAntimetabolitesCalendarCancer BiologyCancer CenterCancer HospitalCancer PatientCaringClinicalClinical OncologyClinical ResearchClinical TrialsClinical Trials Cooperative GroupComprehensive Cancer CenterCooperative Group ProgramDermatologyDisciplineDiseaseDoctor of MedicineEnsureFund RaisingFundingGeneral HospitalsGrantGynecologic OncologyHealthHematologyHospitalsInstitutesIntentionLaboratoriesLeadLeadershipMalignant NeoplasmsMassachusettsMedical OncologyMentorsMentorshipNational Clinical Trials NetworkOperations ResearchOperative Surgical ProceduresPersonnel StaffingPharmacologyPhysiciansPositioning AttributePrincipal InvestigatorRadiation OncologyRecording of previous eventsRecruitment ActivityResearchResearch InfrastructureResearch PersonnelResourcesSiteSupervisionSurgeonSystemTimeTrainingTranslational ResearchUnited StatesUniversitiesVisionWarWorkYale Cancer Centerbasecancer pharmacologycancer research center directorcancer therapycareerdrug developmentmedical schoolsmeetingsnext generationprogramsresponsestandard of care
项目摘要
DESCRIPTION (provided by applicant): This application proposes that Yale University become a Network Lead Academic Participating Site (LAPS) under the newly established NCI National Clinical Trials Network. As an LAPS Yale University will 1. Promote and advocate for NCTN clinical research at the Yale Comprehensive Cancer Center (YCC); 2.continue expanding accrual to NCTN trials and provide broad based access to these important national trials to YCC membership; 3. Provide the scientific leadership necessary in order to advance the cause of NCI funded research in the NCTN system and lead important trials that will advance cancer treatment and standard of care; 4. Provide the translational science and laboratory support for these NCTN clinical trials; 5. Train and mentor Young Investigators in the NCTN groups and help them to provide the next generation of scientific leadership
描述(由申请人提供):本申请提议耶鲁大学成为新成立的NCI国家临床试验网络下的网络领导学术参与站点(LAPS)。作为一名学生,耶鲁大学将。促进和倡导耶鲁大学综合癌症中心(YCC)的NCTN临床研究;2.继续扩大NCTN试验的应计范围,并向YCC会员提供广泛的机会参加这些重要的国家试验;3. 提供必要的科学领导,以推进NCI在NCTN系统中资助的研究事业,并领导将推进癌症治疗和护理标准的重要试验;4. 为这些NCTN临床试验提供转化科学和实验室支持;5. 培训和指导NCTN小组中的青年研究人员,帮助他们提供下一代科学领导
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HOWARD S HOCHSTER其他文献
HOWARD S HOCHSTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HOWARD S HOCHSTER', 18)}}的其他基金
CLINICAL TRIAL: CETUXIMAB PLUS CAPECITABINE AND OXALIPLATIN FOR METASTATIC COLOR
临床试验:西妥昔单抗加卡培他滨和奥沙利铂治疗转移性颜色
- 批准号:
7718426 - 财政年份:2008
- 资助金额:
$ 55.15万 - 项目类别:
CLINICAL TRIAL: ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCE
临床试验:ALIMTA 和 GEMZAR 治疗晚期胰腺癌和胆道癌
- 批准号:
7718420 - 财政年份:2008
- 资助金额:
$ 55.15万 - 项目类别:
ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCER
ALIMTA 和 GEMZAR 治疗晚期胰腺癌和胆道癌
- 批准号:
7605733 - 财政年份:2007
- 资助金额:
$ 55.15万 - 项目类别:
OXALIPLATIN (ELOXATIN) WITH BORTEZOMIB IN PATIENTS WITH ADVANCED MALIGNANCY
奥沙利铂(ELOXATIN)联合硼替佐米治疗晚期恶性肿瘤患者
- 批准号:
7605716 - 财政年份:2007
- 资助金额:
$ 55.15万 - 项目类别:
ECOG N0147: OXAL PLUS 5-FU/CF W/WO CETUXIMAB IN STAGE III COLON CANCERECOG N0
ECOG N0147:OXAL PLUS 5-FU/CF W/WO 西妥昔单抗治疗 III 期结肠癌RECOG N0
- 批准号:
7605775 - 财政年份:2007
- 资助金额:
$ 55.15万 - 项目类别:
BEVACIZUMAB/CETUXIMAB/IRINOTECAN OR BEVACIZUMAB/CETUXIMAB IN COLORECTAL CANCER
贝伐珠单抗/西妥昔单抗/伊立替康或贝伐珠单抗/西妥昔单抗治疗结直肠癌
- 批准号:
7378324 - 财政年份:2006
- 资助金额:
$ 55.15万 - 项目类别:
ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCER
ALIMTA 和 GEMZAR 治疗晚期胰腺癌和胆道癌
- 批准号:
7378319 - 财政年份:2006
- 资助金额:
$ 55.15万 - 项目类别:
CETUXIMAB PLUS CAPECITABINE AND OXALIPLATIN FOR METASTATIC COLORECTAL CANCER
西妥昔单抗联合卡培他滨和奥沙利铂治疗转移性结直肠癌
- 批准号:
7378335 - 财政年份:2006
- 资助金额:
$ 55.15万 - 项目类别:
OXALIPLATIN (ELOXATIN) WITH BORTEZOMIB IN PATIENTS WITH ADVANCED MALIGNANCY
奥沙利铂(ELOXATIN)联合硼替佐米治疗晚期恶性肿瘤患者
- 批准号:
7378298 - 财政年份:2006
- 资助金额:
$ 55.15万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 55.15万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 55.15万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 55.15万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 55.15万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 55.15万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 55.15万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 55.15万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 55.15万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 55.15万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 55.15万 - 项目类别: